Alkermes (NASDAQ:ALKS) Azioni

Alkermes

Alkermes PLC is a fully integrated biotechnology company that applies its proprietary technologies to research, develop, and commercialize pharmaceutical products designed for unmet medical needs in therapeutic areas. The company utilizes several to develop and commercialize products and, in so doing, access technological, financial, marketing, manufacturing, and other resources. Alkermes either purchases active drug products from third parties or receives them from its third-party licensees to formulate products using its technologies. It operates in U.S., which derives maximum revenue, Ireland and Rest of the world.

Alkermes PLC

ALKERMES PLC ORD

– Multiple Subgroup Analyses Presented From Long-Term Safety Study of LYBALVI&#xAE; (olanzapine and samidorphan), Including Data on Lipid and Glycemic Profiles –
DUBLIN, June 2, 2025 /PRNewswire/ -- <a href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=4439097-1&amp;h=841886729&amp;u=https%3A%2F%2Fwww.alkermes.com%2F&amp;a=Alkermes+plc">Alkermes plc</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALKS#NASDAQ">ALKS</a>) today announced the presentation of accepted research at key scientific conferences this spring, including presentations largely related to its psychiatry products LYBALVI&#xAE; (olanzapine and samidorphan) and ARISTADA&#xAE; (aripiprazole lauroxil). Several of these meetings coincided with Mental Health Awareness Month in May, an important moment to raise awareness about mental health conditions, support the millions of people living with these complex diseases, and acknowledge the critical work of healthcare providers. The meetings included:
<ul>
<li>American Association of Psychiatric Pharmacists (AAPP) Annual Meeting, April 27-30, Salt Lake City</li>
<li>The Neuroscience Education Institute (NEI) Spring Congress, May 8-10, Philadelphia</li>
<li>The Professional Society for Health Economics and Outcomes Research (ISPOR) Annual Conference, May 13-16, Montreal</li>
<li>American Psychiatric Association (APA), May 17-21, Los Angeles</li>
<li>American Society of Clinical Psychopharmacology (ASCP) Annual Meeting, May 27-30, Scottsdale</li>
<li>Psych Congress Elevate, May 28-31, Las Vegas</li>
</ul>

News

ALKS

Alkermes Highlights LYBALVI And ARISTADA Data At Key Scientific Conferences

During the last three months, 6 analysts shared their evaluations of Alkermes (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALKS#NASDAQ">ALKS</a>), revealing diverse outlooks from bullish to bearish.
The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
In the assessment of 12-month price targets, analysts unveil insights for Alkermes, presenting an average target of $41.83, a high estimate of $52.00, and a low estimate of $33.00. Witnessing a positive shift, the current average has risen by 7.95% from the previous average price target of $38.75.
<img src="https://www.benzinga.com/files/images/story/2025/1748440916_0.png" alt="price target chart" />
<h2>Investigating Analyst Ratings: An Elaborate Study</h2>
An in-depth analysis of recent analyst actions unveils how financial experts perceive Alkermes. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ami Fadia</td>
<td>Needham</td>
<td>Announces</td>
<td>Buy</td>
<td>$45.00</td>
<td>-</td>
</tr>
<tr>
<td>Leonid Timashev</td>
<td>RBC Capital</td>
<td>Raises</td>
<td>Sector Perform</td>
<td>$40.00</td>
<td>$39.00</td>
</tr>
<tr>
<td>Joel Beatty</td>
<td>Baird</td>
<td>Raises</td>
<td>Outperform</td>
<td>$41.00</td>
<td>$38.00</td>
</tr>
<tr>
<td>Ashwani Verma</td>
<td>UBS</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$33.00</td>
<td>$38.00</td>
</tr>
<tr>
<td>David Hoang</td>
<td>Deutsche Bank</td>
<td>Raises</td>
<td>Buy</td>
<td>$52.00</td>
<td>$40.00</td>
</tr>
<tr>
<td>Leonid Timashev</td>
<td>RBC Capital</td>
<td>Announces</td>
<td>Sector Perform</td>
<td>$40.00</td>
<td>-</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Alkermes. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Analyzing trends, analysts offer qualitative evaluations, ranging from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Alkermes compared to the broader market.</li>
<li>Price Targets: Analysts provide insights into price targets, offering estimates for the future value of Alkermes's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Analyzing these analyst evaluations alongside relevant financial metrics can provide a comprehensive view of Alkermes's market position. Stay informed and make data-driven decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/ALKS/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Alkermes analyst ratings.</a>
<h2>All You Need to Know About Alkermes</h2>
Alkermes PLC is a fully integrated biotechnology company that applies its proprietary technologies to research, develop, and commercialize pharmaceutical products designed for unmet medical needs in therapeutic areas. The company utilizes several to develop and commercialize products and, in so doing, access technological, financial, marketing, manufacturing, and other resources. Alkermes either purchases active drug products from third parties or receives them from its third-party licensees to formulate products using its technologies. It operates in U.S., which derives maximum revenue, Ireland and Rest of the world.
<h3>A Deep Dive into Alkermes's Financials</h3>
Market Capitalization Perspectives: The company's market capitalization falls below industry averages, signaling a relatively smaller size compared to peers. This positioning may be influenced by factors such as perceived growth potential or operational scale.
Revenue Growth: Alkermes's revenue growth over a period of 3M has faced challenges. As of 31 March, 2025, the company experienced a revenue decline of approximately -12.52%. This indicates a decrease in the company's top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Health Care sector.
Net Margin: Alkermes's net margin is impressive, surpassing industry averages. With a net margin of 7.33%, the company demonstrates strong profitability and effective cost management.
Return on Equity (ROE): Alkermes's ROE excels beyond industry benchmarks, reaching 1.51%. This signifies robust financial management and efficient use of shareholder equity capital.
Return on Assets (ROA): Alkermes's financial strength is reflected in its exceptional ROA, which exceeds industry averages. With a remarkable ROA of 1.09%, the company showcases efficient use of assets and strong financial health.
Debt Management: Alkermes's debt-to-equity ratio is below the industry average. With a ratio of 0.05, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.
<h2>What Are Analyst Ratings?</h2>
Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the upcoming five years, and how risky or predictable that company's revenue streams are.
Analysts attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish their ratings on stocks. Analysts typically rate each stock once per quarter or whenever the company has a major update.
Some analysts also offer predictions for helpful metrics such as earnings, revenue, and growth estimates to provide further guidance as to what to do with certain tickers. It is important to keep in mind that while stock and sector analysts are specialists, they are also human and can only forecast their beliefs to traders.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Analyst Ratings

Alkermes Stock: A Deep Dive Into Analyst Perspectives (6 Ratings)

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.
<ul class="wp-block-list">
<li>Needham analyst Ami Fadia initiated coverage on Alkermes plc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALKS#NASDAQ">ALKS</a>) with a Buy rating and announced a price target of $45. Alkermes shares closed at $29.90 on Tuesday. <a href="https://www.benzinga.com/quote/ALKS/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>HC Wainwright &amp; Co. analyst Yi Chen initiated coverage on NeuroPace, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NPCE#NASDAQ">NPCE</a>) with a Buy rating and announced a price target of $18. NeuroPace shares closed at $12.66 on Tuesday. <a href="https://www.benzinga.com/quote/NPCE/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Wedbush analyst Martin Fan initiated coverage on Aclaris Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACRS#NASDAQ">ACRS</a>) with an Outperform rating and announced a price target of $8. Aclaris Therapeutics shares closed at $1.27 on Tuesday. <a href="https://www.benzinga.com/quote/ACRS/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Redburn Atlantic analyst Mike Harrison initiated coverage on Marvell Technology, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRVL#NASDAQ">MRVL</a>) with a Neutral rating and announced a price target of $67. Marvell Tech shares closed at $63.82 on Tuesday. <a href="https://www.benzinga.com/quote/MRVL/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Redburn Atlantic analyst Mike Harrison initiated coverage on Arista Networks Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ANET#NYSE">ANET</a>) with a Buy rating and announced a price target of $112. Arista Networks shares closed at $92.49 on Tuesday. <a href="https://www.benzinga.com/quote/ANET/analyst-ratings">See how other analysts view this stock.</a></li>
</ul>
Considering buying ANET stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="595" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/28074230/image-356-1024x595.png" alt="" class="wp-image-929704" style="width:603px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/28074230/image-356-1024x595.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/28074230/image-356-300x174.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/28074230/image-356-768x446.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/28074230/image-356.png 1102w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read This Next: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/trading-ideas/long-ideas/25/05/45616471/jim-cramer-says-rocket-is-a-very-fine-company-recommends-buying-this-health-care-stock">Jim Cramer Says Rocket Is A &#8216;Very Fine&#8217; Company, Recommends Buying This Health Care Stock</a> </li>
</ul>
Photo via Shutterstock

Price Target

Initiation

Pre-Market Outlook

Markets

Trading Ideas

ACRS

ANET

MRVL

NPCE

This Arista Networks Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday

Needham analyst Ami Fadia initiates coverage on Alkermes (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALKS#NASDAQ">ALKS</a>) with a Buy rating and announces Price Target of $45.

Needham Initiates Coverage On Alkermes with Buy Rating, Announces Price Target of $45

RBC Capital analyst Leonid Timashev maintains Alkermes (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALKS#NASDAQ">ALKS</a>) with a Sector Perform and raises the price target from $39 to $40.

RBC Capital Maintains Sector Perform on Alkermes, Raises Price Target to $40

Baird analyst Joel Beatty maintains Alkermes (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALKS#NASDAQ">ALKS</a>) with a Outperform and raises the price target from $38 to $41.

Baird Maintains Outperform on Alkermes, Raises Price Target to $41

WIIM

Alkermes shares are trading higher after the company reported Q1 financial results and beat its EPS and revenue estimates.

Alkermes (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALKS#NASDAQ">ALKS</a>) affirms FY2025 GAAP EPS guidance from $1.03-$1.21 to $1.03-$1.21 vs $1.12 analyst estimate. Affirms FY2025 sales outlook from $1.34 billion-$1.43 billion to $1.34 billion-$1.43 billion vs $1.39 billion estimate.

Guidance

Alkermes Affirms FY2025 GAAP EPS Guidance of $1.03-$1.21 vs $1.12 Est; Affirms FY2025 Sales Guidance of $1.34B-$1.43B vs $1.39B Est

Alkermes (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALKS#NASDAQ">ALKS</a>) reported quarterly earnings of $0.13 per share which beat the analyst consensus estimate of $0.05 by 160 percent. This is a 38.1 percent decrease over earnings of $0.21 per share from the same period last year. The company reported quarterly sales of $306.51 million which beat the analyst consensus estimate of $304.12 million by 0.79 percent. This is a 12.52 percent decrease over sales of $350.37 million the same period last year.

Earnings

Earnings Beats

Alkermes Q1 GAAP EPS $0.13 Beats $0.05 Estimate, Sales $306.51M Beat $304.12M Estimate

AAMI

AAPL

ABNB

ACCO

ADPT

AGCO

AGIO

ALHC

ALNY

ALSN

AMGN

AMWL

AMZN

APLE

APTV

ARDX

ARVN

ASND

ASPS

ASUR

ATEC

ATEN

AXTI

BBAI

BIIB

BJRI

BLDR

BMRN

BOOM

BPMC

BRFH

CABO

CARR

CART

CERS

CMLS

COHN

COHU

COLM

COMM

COOK

CRAI

CTRE

CUBE

CWST

DBRG

DINO

DSGR

DUOL

DXCM

ECVT

ELME

Earnings Scheduled For May 1, 2025

Ratings for Alkermes (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALKS#NASDAQ">ALKS</a>) were provided by 6 analysts in the past three months, showcasing a mix of bullish and bearish perspectives.
The following table provides a quick overview of their recent ratings, highlighting the changing sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts have recently evaluated Alkermes and provided 12-month price targets. The average target is $40.5, accompanied by a high estimate of $52.00 and a low estimate of $32.00. This upward trend is apparent, with the current average reflecting a 5.19% increase from the previous average price target of $38.50.
<img src="https://www.benzinga.com/files/images/story/2025/1745877632_0.png" alt="price target chart" />
<h2>Breaking Down Analyst Ratings: A Detailed Examination</h2>
In examining recent analyst actions, we gain insights into how financial experts perceive Alkermes. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
&#x7C; Analyst &#x7C; Analyst Firm &#x7C; Action Taken &#x7C; Rating &#x7C;Current Price Target&#x7C; Prior Price Target &#x7C; 
&#x7C;--------------------&#x7C;--------------------&#x7C;---------------&#x7C;---------------&#x7C;--------------------&#x7C;--------------------&#x7C; 
&#x7C;Ashwani Verma &#x7C;UBS &#x7C;Lowers &#x7C;Neutral &#x7C; $33.00&#x7C;$38.00 &#x7C; 
&#x7C;David Hoang &#x7C;Deutsche Bank &#x7C;Raises &#x7C;Buy &#x7C; $52.00&#x7C;$40.00 &#x7C; 
&#x7C;Leonid Timashev &#x7C;RBC Capital &#x7C;Announces &#x7C;Sector Perform &#x7C; $40.00&#x7C;- &#x7C; 
&#x7C;Chris Shibutani &#x7C;Goldman Sachs &#x7C;Raises &#x7C;Buy &#x7C; $32.00&#x7C;$30.00 &#x7C; 
&#x7C;Douglas Tsao &#x7C;HC Wainwright &amp; Co. &#x7C;Maintains &#x7C;Neutral &#x7C; $46.00&#x7C;$46.00 &#x7C; 
&#x7C;David Hoang &#x7C;Deutsche Bank &#x7C;Announces &#x7C;Buy &#x7C; $40.00&#x7C;- &#x7C;
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to Alkermes. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li>Rating: Analysts assign qualitative assessments to stocks, ranging from 'Outperform' to 'Underperform'. These ratings convey the analysts' expectations for the relative performance of Alkermes compared to the broader market.</li>
<li>Price Targets: Analysts predict movements in price targets, offering estimates for Alkermes's future value. Examining the current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
Understanding these analyst evaluations alongside key financial indicators can offer valuable insights into Alkermes's market standing. Stay informed and make well-considered decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/ALKS/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Alkermes analyst ratings.</a>
<h2>Delving into Alkermes's Background</h2>
Alkermes PLC is a fully integrated biotechnology company that applies its proprietary technologies to research, develop, and commercialize pharmaceutical products designed for unmet medical needs in therapeutic areas. The company utilizes several to develop and commercialize products and, in so doing, access technological, financial, marketing, manufacturing, and other resources. Alkermes either purchases active drug products from third parties or receives them from its third-party licensees to formulate products using its technologies. It operates in U.S., which derives maximum revenue, Ireland and Rest of the world.
<h3>Alkermes: A Financial Overview</h3>
Market Capitalization Analysis: Reflecting a smaller scale, the company's market capitalization is positioned below industry averages. This could be attributed to factors such as growth expectations or operational capacity.
Revenue Growth: Alkermes displayed positive results in 3M. As of 31 December, 2024, the company achieved a solid revenue growth rate of approximately 13.91%. This indicates a notable increase in the company's top-line earnings. When compared to others in the Health Care sector, the company faces challenges, achieving a growth rate lower than the average among peers.
Net Margin: The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of 34.07%, the company showcases strong profitability and effective cost control.
Return on Equity (ROE): Alkermes's ROE stands out, surpassing industry averages. With an impressive ROE of 10.63%, the company demonstrates effective use of equity capital and strong financial performance.
Return on Assets (ROA): Alkermes's financial strength is reflected in its exceptional ROA, which exceeds industry averages. With a remarkable ROA of 6.96%, the company showcases efficient use of assets and strong financial health.
Debt Management: Alkermes's debt-to-equity ratio is below the industry average at 0.05, reflecting a lower dependency on debt financing and a more conservative financial approach.
<h2>Analyst Ratings: Simplified</h2>
Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.
In addition to their assessments, some analysts extend their insights by offering predictions for key metrics such as earnings, revenue, and growth estimates. This supplementary information provides further guidance for traders. It is crucial to recognize that, despite their specialization, analysts are human and can only provide forecasts based on their beliefs.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Beyond The Numbers: 6 Analysts Discuss Alkermes Stock

UBS analyst Ashwani Verma maintains Alkermes (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALKS#NASDAQ">ALKS</a>) with a Neutral and lowers the price target from $38 to $33.

UBS Maintains Neutral on Alkermes, Lowers Price Target to $33

<ul>
<li>Vibrance-3 is a phase 2, randomized, double-blind, dose-range-finding, placebo-controlled study evaluating the safety and efficacy of ALKS 2680 in adults with IH. Participants will be randomized to receive one of three doses of ALKS 2680 (10 mg, 14 mg or 18 mg) or placebo to be taken once-daily for eight weeks.&nbsp;</li>
<li>The primary endpoint will assess, by dose level, whether participants taking ALKS 2680 experience a greater decrease in sleepiness compared to participants taking placebo alone, as measured by the change in Epworth Sleepiness Scale (ESS) score.&nbsp;</li>
<li>Secondary endpoints include change in Idiopathic Hypersomnia Severity Scale (IHSS) score and incidence of adverse events.&nbsp;The study is expected to enroll approximately 96 patients with IH across sites in the U.S., Australia and Europe.&nbsp;</li>
<li>Participants who complete the study will be eligible to continue in a long-term, open-label, safety study (NCT06767683).</li>
</ul>

Biotech

Health Care

General

Alkermes Has Initiated Vibrance-3 Phase 2 Study Evaluating The Safety And Efficacy Of ALKS 2680 Compared To Placebo In Adults With Idiopathic Hypersomnia

Analysts' ratings for Alkermes (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALKS#NASDAQ">ALKS</a>) over the last quarter vary from bullish to bearish, as provided by 5 analysts.
In the table below, you'll find a summary of their recent ratings, revealing the shifting sentiments over the past 30 days and comparing them to the previous months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts have set 12-month price targets for Alkermes, revealing an average target of $42.0, a high estimate of $52.00, and a low estimate of $32.00. This upward trend is evident, with the current average reflecting a 8.61% increase from the previous average price target of $38.67.
<img src="https://www.benzinga.com/files/images/story/2025/1743076830_0.png" alt="price target chart" />
<h2>Interpreting Analyst Ratings: A Closer Look</h2>
In examining recent analyst actions, we gain insights into how financial experts perceive Alkermes. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>David Hoang</td>
<td>Deutsche Bank</td>
<td>Raises</td>
<td>Buy</td>
<td>$52.00</td>
<td>$40.00</td>
</tr>
<tr>
<td>Leonid Timashev</td>
<td>RBC Capital</td>
<td>Announces</td>
<td>Sector Perform</td>
<td>$40.00</td>
<td>-</td>
</tr>
<tr>
<td>Chris Shibutani</td>
<td>Goldman Sachs</td>
<td>Raises</td>
<td>Buy</td>
<td>$32.00</td>
<td>$30.00</td>
</tr>
<tr>
<td>Douglas Tsao</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Neutral</td>
<td>$46.00</td>
<td>$46.00</td>
</tr>
<tr>
<td>David Hoang</td>
<td>Deutsche Bank</td>
<td>Announces</td>
<td>Buy</td>
<td>$40.00</td>
<td>-</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Alkermes. This offers insight into analysts' perspectives on the current state of the company.</li>
<li>Rating: Delving into assessments, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings communicate expectations for the relative performance of Alkermes compared to the broader market.</li>
<li>Price Targets: Analysts provide insights into price targets, offering estimates for the future value of Alkermes's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Assessing these analyst evaluations alongside crucial financial indicators can provide a comprehensive overview of Alkermes's market position. Stay informed and make well-judged decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/ALKS/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Alkermes analyst ratings.</a>
<h2>Get to Know Alkermes Better</h2>
Alkermes PLC is a fully integrated biotechnology company that applies its proprietary technologies to research, develop, and commercialize pharmaceutical products designed for unmet medical needs in therapeutic areas. The company utilizes several to develop and commercialize products and, in so doing, access technological, financial, marketing, manufacturing, and other resources. Alkermes either purchases active drug products from third parties or receives them from its third-party licensees to formulate products using its technologies. It operates in U.S., which derives maximum revenue, Ireland and Rest of the world.
<h3>Financial Insights: Alkermes</h3>
Market Capitalization Analysis: With a profound presence, the company's market capitalization is above industry averages. This reflects substantial size and strong market recognition.
Revenue Growth: Alkermes displayed positive results in 3 months. As of 31 December, 2024, the company achieved a solid revenue growth rate of approximately 13.91%. This indicates a notable increase in the company's top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: Alkermes's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 34.07% net margin, the company effectively manages costs and achieves strong profitability.
Return on Equity (ROE): The company's ROE is a standout performer, exceeding industry averages. With an impressive ROE of 10.63%, the company showcases effective utilization of equity capital.
Return on Assets (ROA): Alkermes's financial strength is reflected in its exceptional ROA, which exceeds industry averages. With a remarkable ROA of 6.96%, the company showcases efficient use of assets and strong financial health.
Debt Management: Alkermes's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 0.05.
<h2>How Are Analyst Ratings Determined?</h2>
Analyst ratings serve as essential indicators of stock performance, provided by experts in banking and financial systems. These specialists diligently analyze company financial statements, participate in conference calls, and engage with insiders to generate quarterly ratings for individual stocks.
Analysts may enhance their evaluations by incorporating forecasts for metrics like growth estimates, earnings, and revenue, delivering additional guidance to investors. It is vital to acknowledge that, although experts in stocks and sectors, analysts are human and express their opinions when providing insights.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

What 5 Analyst Ratings Have To Say About Alkermes

Deutsche Bank analyst David Hoang maintains Alkermes (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALKS#NASDAQ">ALKS</a>) with a Buy and raises the price target from $40 to $52.

Deutsche Bank Maintains Buy on Alkermes, Raises Price Target to $52

RBC Capital analyst Leonid Timashev initiates coverage on Alkermes (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALKS#NASDAQ">ALKS</a>) with a Sector Perform rating and announces Price Target of $40.

RBC Capital Initiates Coverage On Alkermes with Sector Perform Rating, Announces Price Target of $40

Goldman Sachs analyst Chris Shibutani maintains Alkermes (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALKS#NASDAQ">ALKS</a>) with a Buy and raises the price target from $30 to $32.

Goldman Sachs Maintains Buy on Alkermes, Raises Price Target to $32

HC Wainwright &amp; Co. analyst Douglas Tsao reiterates Alkermes (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALKS#NASDAQ">ALKS</a>) with a Neutral and maintains $46 price target.

Reiteration

HC Wainwright & Co. Reiterates Neutral on Alkermes, Maintains $46 Price Target

A hotter-than-expected inflation report initially rattled markets on Wednesday morning, but investors found confidence to buy the dip, helping major indexes recover most losses by <a href="https://www.benzinga.com/government/regulations/25/02/43656846/inflation-rises-more-than-expected-in-january-chills-interest-rate-cut-hopes">midday trading in New York.</a>
The S&amp;P 500 was down 0.2%, while the Nasdaq 100 was flat, both rebounding from sharp declines following the January Consumer Price Index report. Small-cap stocks underperformed, with the Russell 2000 slipping 0.8%.
The headline CPI rose 3% year over year in January, surpassing both December's 2.9% reading and economist forecasts of 2.9%. On a monthly basis, inflation increased 0.5%, outpacing expectations of 0.3% and accelerating from December's 0.4% gain. This marked the fastest monthly inflation rate since August 2023.
Core inflation, which excludes food and energy, climbed to 3.3% year over year from 3.2% in December. On a monthly basis, core CPI increased 0.4%, exceeding estimates of 0.3% and doubling December's 0.2% rise.
Treasuries and interest rate markets reacted sharply to the inflation data. Traders scaled back expectations for Federal Reserve rate cuts, now projecting only one reduction by December 2025.
Treasury yields surged, reflecting heightened investor uncertainty. The 10-year Treasury yield jumped 10 basis points to 4.64%. The iShares 20+ Year Treasury Bond ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TLT#NASDAQ">TLT</a>) fell 1%.
Despite rising Treasury yields and a stronger dollar, gold edged up 0.2% to $2,910 per ounce. Oil prices dropped 2% after reports that Donald Trump spoke with Russian President Vladimir Putin, fueling speculation about a potential ceasefire in Ukraine.
Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) also rebounded from earlier session losses.
<h3 class="wp-block-heading">Wednesday&#8217;s Performance In Major US Indices, ETFs</h3>
<figure class="wp-block-table is-style-stripes"> 
<table>
<tbody>
<tr>
<td>Major Indices</td>
<td>Price</td>
<td>1-day %chg</td>
</tr>
<tr>
<td>Nasdaq 100</td>
<td>21,688.40</td>
<td>0.0%</td>
</tr>
<tr>
<td>S&amp;P 500</td>
<td>6,056.85</td>
<td>-0.2%</td>
</tr>
<tr>
<td>Dow Jones</td>
<td>44,411.00</td>
<td>-0.4%</td>
</tr>
<tr>
<td>Russell 2000</td>
<td>2,257.59</td>
<td>-0.8%</td>
</tr>
</tbody>
</table>
<figcaption class="wp-element-caption">Updated at 12:45 p.m. ET</figcaption></figure>
According to&nbsp;<a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent020325&amp;t=be2bearmibe3na1" target="_blank" rel="noreferrer noopener">Benzinga Pro</a>&nbsp;data:
<ul>
<li>The&nbsp;SPDR S&amp;P 500 ETF Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>)&nbsp;inched 0.2% down to $603.77.</li>
<li>The&nbsp;SPDR Dow Jones Industrial Average&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DIA#NYSE">DIA</a>) was 0.4% down to $444.41.</li>
<li>The tech-heavy&nbsp;Invesco QQQ Trust Series&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QQQ#NASDAQ">QQQ</a>)&nbsp;flattened at $528.09.</li>
<li>The&nbsp;iShares Russell 2000 ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IWM#NYSE">IWM</a>) eased 0.8% to $224.</li>
<li>The&nbsp;Consumer Discretionary Select Sector SPDR Fund (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLY#NYSE">XLY</a>) outperformed, up 0.4%; the&nbsp;Energy Select Sector SPDR Fund&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLE#NYSE">XLE</a>) lagged, down 1.2%.</li>
</ul>
Wednesday&#8217;s Stock Movers
<ul>
<li>Tesla Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) jumped more than 4% after the electric vehicle maker tumbled 6.3% on Tuesday, reaching oversold levels and extending its losing streak to five consecutive sessions.</li>
</ul>
Stocks reacting to company earnings reports included: 
<ul>
<li>CVS Health Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVS#NYSE">CVS</a>): up 15.7%</li>
<li>Super Micro Computer Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMCI#NASDAQ">SMCI</a>): up 4.5%</li>
<li>Edwards Lifesciences Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EW#NYSE">EW</a>): up 5.6%</li>
<li>América Móvil, S.A.B. de C.V. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AMX#NYSE">AMX</a>): down 1.4%</li>
<li>American International Group Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AIG#NYSE">AIG</a>): up 0.2%</li>
<li>Energy Transfer LP (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ET#NYSE">ET</a>): up 0.3%</li>
<li>Southern Copper Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SCCO#NYSE">SCCO</a>): up 2.9%</li>
<li>Gilead Sciences Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GILD#NASDAQ">GILD</a>): up 6.8%</li>
<li>Zillow Group Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/Z#NASDAQ">Z</a>): down 10.2%</li>
<li>CME Group Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CME#NASDAQ">CME</a>): up 2.2%</li>
<li>Chimera Investment Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CIM#NYSE">CIM</a>): down 8.9%</li>
<li>Ryder System Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/R#NYSE">R</a>): up 4.0%</li>
<li>Smurfit WestRock Plc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SW#NYSE">SW</a>): down 5.8%</li>
<li>Sonic Automotive Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SAH#NYSE">SAH</a>): down 2.4%</li>
<li>Alkermes Plc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALKS#NASDAQ">ALKS</a>): up 4.1%</li>
<li>Anavex Life Sciences Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AVXL#NASDAQ">AVXL</a>): up 1.0%</li>
<li>Biogen Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BIIB#NASDAQ">BIIB</a>): down 4.6%</li>
<li>Blackstone Mortgage Trust Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BXMT#NYSE">BXMT</a>): up 2.8%</li>
<li>Camtek Ltd/Israel (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CAMT#NASDAQ">CAMT</a>): up 1.5%</li>
<li>Chefs' Warehouse Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CHEF#NASDAQ">CHEF</a>): up 13.0%</li>
<li>Diebold Nixdorf Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DBD#NYSE">DBD</a>): down 3.2%</li>
<li>Dominion Energy Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/D#NYSE">D</a>): up 0.6%</li>
<li>Exelon Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EXC#NASDAQ">EXC</a>): up 0.4%</li>
</ul>
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/25/02/43663963/record-high-egg-prices-drive-inflation-higher-in-january">Record-High Egg Prices Drive Inflation Higher In January</a></li>
</ul>
Illustration created using artificial intelligence via Midjourney.

Equities

Large Cap

Commodities

Economics

Federal Reserve

Tech

ETFs

$BTC

AVXL

BXMT

CAMT

CHEF

SPDR Dow Jones Industrial Average ETF Trust

GILD

SCCO

SMCI

iShares Trust Barclays 20+ Year Treasury Bond Fund

TSLA

Select Sector SPDR-Consumer Discretionary

Stocks Trim Losses After Hot Inflation, Bonds Remain Pressured, Tesla Rebounds: What's Driving Markets Wednesday?

Financial Expectations for 2025
All line items are according to GAAP, except as otherwise noted.
<figure class="table"> 
<table>
<tbody>
<tr>
<td colspan="1" rowspan="1">In millions</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1">2025 Expectations</td>
</tr>
<tr>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Total Revenues&nbsp;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1">$1,340 – $1,430</td>
</tr>
<tr>
<td colspan="1" rowspan="1">VIVITROL Net Sales</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1">$440 – $460</td>
</tr>
<tr>
<td colspan="1" rowspan="1">ARISTADAi Net Sales</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1">$335 – $355</td>
</tr>
<tr>
<td colspan="1" rowspan="1">LYBALVI Net Sales</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1">$320 – $340</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Cost of Goods Sold</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1">$185 – $205</td>
</tr>
<tr>
<td colspan="1" rowspan="1">R&amp;D Expenses</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1">$305 – $335</td>
</tr>
<tr>
<td colspan="1" rowspan="1">SG&amp;A Expenses</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1">$655 – $685</td>
</tr>
<tr>
<td colspan="1" rowspan="1">GAAP Net Income a</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1">$175 – $205</td>
</tr>
<tr>
<td colspan="1" rowspan="1">EBITDA</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1">$215 – $245</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Adjusted EBITDA</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1">$310 – $340</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Effective Tax Rate</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1">~17%</td>
</tr>
</tbody>
</table>
</figure>

Alkermes Forecasts 2025 Sales Of $1.34B-$1.43B Versus Consensus Of $1.40B

Press Releases

Alkermes to Participate in Upcoming Investor Conferences

New National Survey of Healthcare Providers Offers Insights Into the Dynamic and Challenging Treatment Journey for People Living With Schizophrenia or Bipolar I Disorder

Alkermes Announces Initiation of Vibrance-3 Phase 2 Study Evaluating ALKS 2680 for the Treatment of Idiopathic Hypersomnia

Alkermes to Participate in the 24th Annual Needham Virtual Healthcare Conference

Alkermes to Report First Quarter Financial Results on May 1, 2025

New Survey Provides Insights into Diagnosis and Treatment Journey for People Living With Alcohol Use Disorder (AUD)

Alkermes plc Reports First Quarter 2025 Financial Results

Alkermes to Present New Research Related to ALKS 2680 at SLEEP 2025

Alkermes Highlights Data From Psychiatry Portfolio at Spring 2025 Scientific Conferences

Alkermes to Participate in the 46th Annual Goldman Sachs Global Healthcare Conference

Comments

Alkermes

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO